Elevated brain-derived cell-free DNA among patients with first psychotic episode - a proof-of-concept study

3

4	Asael Lubotzky ^{1, 2,*} , Ilana pelov ^{3,*} , Ronen Teplitz ³ , Daniel Neiman ¹ , Adama Smadja ³ , Hai
5	Zemmour ¹ , Sheina Piyanzin ¹ , Bracha-Lea Ochana ¹ , Kirsty L. Spalding ⁴ , Benjamin Glaser ⁵ , Ruth
6	Shemer ^{1,†} , Yuval Dor ^{1,†} , Yoav Kohn ^{3,6,†}
7	¹ Department of Developmental Biology and Cancer Research, Institute for Medical Research
8	Israel-Canada, the Hebrew University-Hadassah Medical School, Jerusalem, Israel
9	² Neuropediatric Unit, Shaare Zedek Medical Center, Jerusalem, Israel
10	³ Jerusalem Mental Health Center, Eitanim Psychiatric Hospital, Jerusalem, Israel.
11	⁴ Karolinska Institute, Department of Cell and Molecular Biology Stockholm, Stockholm,
12	Sweden.
13	⁵ Department of Endocrinology and Metabolism Service, Hadassah Medical Organization and
14	Faculty of Medicine, Hebrew University of Jerusalem, Israel.
15	⁶ Hebrew University-Hadassah School of Medicine, Jerusalem, Israel.
16	*These authors contributed equally to this work
17	[†] Co-senior authors.
18	

19 Address correspondence to:

20	Ruth Shemer or Yuval Dor, Department of Developmental Biology and Cancer Research, The
21	Hebrew University-Hadassah Medical School, Ein Kerem Campus, Jerusalem 91120, Israel.
22	Phone: 972.2.6757181; Email: shemer.ru@mail.huji.ac.il (RS). Phone: 972.2.6757181; Email:
23	yuvald@ekmd.huji.ac.il (YD). Or to: Yoav Kohn, Jerusalem Mental Health Center, Eitanim
24	Psychiatric Hospital, Jerusalem, Israel. Phone: 972.2.6551303; Email: yoavk@ekmd.huji.ac.il
25	

- 26 Short/running title: Brain cell-free DNA in acute psychosis
- 27 Six keywords: Psychosis, cfDNA, DNA methylation, Liquid biopsy, Epigenetics, Biomarker.

29 Abstract

31	Background: Schizophrenia is a common, severe and debilitating psychiatric disorder. Despite
32	extensive research there is as yet no biological marker that can aid in its diagnosis and course
33	prediction. This precludes early detection and intervention. Imaging studies suggest brain
34	volume loss around the onset and over the first few years of schizophrenia, and apoptosis has
35	been proposed as the underlying mechanism. Cell free DNA fragments (cfDNA) are released
36	into the bloodstream following cell death. Tissue-specific methylation patterns allow the
37	identification of the tissue origins of cfDNA.
38	Methods: We developed a cocktail of brain specific DNA methylation markers, and used it to
39	assess the presence of brain-derived cfDNA in the plasma of patients with a first psychotic
40	episode.
41	Results : We detected significantly elevated neuron- (p=0.0013), astrocyte- (p=0.0016),
42	oligodendrocyte- (p=0.0129) and whole brain-derived (p=0.0012) cfDNA in the plasma of
43	patients during their first psychotic episode (n=29), compared with healthy controls (n=31).
44	Increased cfDNA levels were not correlated with psychotropic medications use. Area Under the
45	Curve (AUC) was 0.77, with 65% sensitivity at 90% specificity in patients with a psychotic
46	enisode
	episode.
47	Conclusions : Potential interpretations of these findings include increased brain cell death,
47 48	Conclusions : Potential interpretations of these findings include increased brain cell death, disruption of the blood brain barrier or a defect in clearance of material from dying brain cells.
47 48 49	Conclusions: Potential interpretations of these findings include increased brain cell death,disruption of the blood brain barrier or a defect in clearance of material from dying brain cells.Brain-specific cfDNA methylation markers can potentially assist early detection and monitoring

51 Introduction

52 Early diagnosis in schizophrenia

53 Schizophrenia is a complex and chronic psychiatric disorder affecting around 1% of the global

54 population. It is associated with increased disability, mortality and high private and social

55 economic burden¹⁻³.

56 Psychosis is the first presentation of schizophrenia that usually leads to the diagnosis. Although

57 psychosis typically onsets during adolescence and young adulthood, there is accumulating data

58 that demonstrates underlying biological changes, beginning years prior to the psychotic

59 symptoms^{4,5}. Thus, identifying biomarkers that will allow early diagnosis and therapeutic

60 interventions is of the highest importance.

61 The etiology of schizophrenia is multifactorial, with a complex interaction of polygenic risk and 62 environmental factors^{3,6}. Although over 100 genetic variants were identified contributing to the

risk of schizophrenia, their broad distribution in the general population precludes clinical use⁷.

64 Other potential biomarkers were studied including neurotransmitters and their metabolites⁸,

65 associated endophenotypes such as smooth pursuit eye movement (SPEM)⁹ and sensory gating

66 defects (P150)¹⁰. Results of those studies are somewhat inconsistent and are not specific enough

to allow their use as a diagnostic tool. Brain imaging has demonstrated notable structural

68 changes mostly in late and more chronic stages of the disease, too late for useful intervention¹¹.

69 Cell free DNA as a biomarker for diseases

70 Circulating cell-free DNA (cfDNA) in the blood plasma was first discovered by Mandel and

71 Metais in 1948¹². Over the years it was established that these typically ~150 bp fragments of

72 double-stranded DNA are released into the blood stream during the process of cell death¹³.

cfDNA molecules are rapidly cleared from the circulation with a half-life of ~15 minutes, thus
reflecting events taking place at the time of blood draw^{14,15}. Although the mechanism underlying
the release and rapid clearance of the cfDNA is still unclear, many researchers have been trying
to develop methods that will enable the use of these short fragments for the diagnosis and followup of various medical conditions. For example, cfDNA-based methods of prenatal diagnosis
have been developed^{16,17}, and ongoing work is advancing approaches for cancer liquid biopsy^{18–}

80 The possibility of using cfDNA as a biomarker in the medical conditions detailed so far is based 81 on the fundamental genetic difference between the DNA of a host and that of a tumor, fetus or 82 the graft^{21,23–26}. In comparison it is more complicated to assess changes in the levels of cfDNA in 83 plasma of healthy individuals or individuals without mutated DNA in their blood. It is known 84 that plasma levels of cfDNA vary over time depending on age, increased physical activity, and 85 the existence of various medical conditions such as infectious diseases¹⁵. Therefore, it has not 86 been possible to use the amount of cfDNA in the blood as a marker for a specific pathology. 87 Moreover, although the cfDNA that circulates in the blood originates from different tissues, it 88 has the same genome and therefore cannot be associated with a specific source tissue using DNA 89 sequencing^{23,27,28}.

90 We and others have recently described an approach to identify the tissue origins of cfDNA,

91 based on tissue-specific methylation patterns. Such cell-type specific markers allow the inference

92 of cell death in multiple settings, for example cardiomyocyte cell death following myocardial

93 infarction or hepatocyte death in patients with liver metastasis $^{21,23-26}$.

94 Brain cell death in psychosis and schizophrenia

95 Neuro-anatomical changes are known in schizophrenia. Numerous longitudinal and cross-96 sectional imaging studies recruited individuals at high and ultra-high risk for developing a 97 psychotic illness and demonstrated dynamic brain changes emerging around onset and over the 98 years of schizophrenia. The studies generally demonstrate gray matter reduction in the frontal and temporo-limbic regions^{29–31}. Structural brain abnormalities in psychosis occur prior to full 99 100 blown symptoms and progressively worsen as psychosis develops. Although the underlying 101 causes and the exact timing of the morphologic changes in the brain remain obscure, apoptosis 102 has been proposed as a potential mechanism that could contribute to this progressive pathology. 103 This idea is also supported by post-mortem evidence of regional reduction of neuronal and glia 104 density. Apoptosis in the CNS occurs rapidly, and apoptotic cells are typically cleared within 24 105 hours. The process occurs without inflammation and does not involve gliosis^{32,33}. Ershove et. al 106 demonstrated dysregulation of apoptosis in schizophrenia through considerably increased oxidated levels of cfDNA³⁴. Thus, we hypothesized that brain-derived cfDNA levels increase in 107 108 patients with acute psychosis and schizophrenia, reflecting ongoing cell death, especially in early 109 and active phases of diseases. We further hypothesized that brain cfDNA levels would be 110 increased in patients, unrelated to treatment with antipsychotic medications.

In this proof-of-concept study we examined plasma samples from patients with a first psychotic episode, in order to assess the potential use of brain cfDNA as a method for early detection and diagnosis of schizophrenia in general and acute psychosis events.

114 Methods

115 Clinical samples

116 We recruited men and women over 18 years of age, who have developed psychotic symptoms for 117 the first time in their life within the last year and were admitted to the acute psychiatric units of 118 the Jerusalem Mental Health Center in Israel. Diagnosis of a psychotic disorder was given by 119 treating psychiatrists and verified by a senior psychiatrist from the research team (I.P.). Blood 120 samples were obtained after the initial stabilization and partial remission of the psychotic 121 symptoms which enabled the patients to give written informed consent for participation in the 122 study. The patients were asked to complete a short questionnaire regarding demographic details, 123 current physical condition, the onset of present symptoms and drug use. The recruitment was 124 done following the approval of the study's protocol by the Jerusalem Mental Health Center 125 Institutional Review Board. Patients with acute medical conditions in the week prior to the blood 126 sampling were excluded from the study. 127 A total of 31 patients were recruited between the years 2017 and 2019. DNA extraction from two 128 samples has failed, and the remaining 29 samples were analyzed. The study included 55% 129 females (n=16) and 45% males (n=13), with an age distribution of 18-48 years (average 24). 130 72.5% of the patients (n=21) were hospitalized with a first psychotic event in their life, and 131 27.5% of the patients (n=8) had a second or third psychotic event, up to a year after the 132 beginning of the first one. 44.8% of the patients (n=13) did not have any background of drug

abuse, 31% (n=9) indicated the use of marijuana in the weeks preceding the onset of the first

134 psychotic episode. 24.2% patients (n=7) described using several different types of drugs

135 (hallucinogens, MDMA, cocaine, etc.) in the past. Clinical data, including medications used,

136 were obtained from medical records.

- 137 31 adult volunteers participated in the study as unpaid healthy controls. The samples were
- 138 compared to age and sex matched healthy control subjects.
- 139 Patient demographics, clinical data and cfDNA data are detailed in **Supplementary Table S1**.
- 140 **cfDNA** analysis

141 Blood samples were collected in cell-free DNA BCT® (Streck) tubes and centrifuged at 1500g 142 for 10 min at 25 °C within 1 week of collection. Plasma was removed and re-centrifuged at 143 3000g for 10 min at 25 °C to remove any remaining cells. Plasma was then stored at -80 °C until 144 assay. Cell-free DNA was extracted using the QIAsymphony SP instrument and its dedicated 145 QIAsymphony Circulating DNA Kit (Qiagen) according to manufacturer's instructions. DNA 146 concentration was measured using the Qubit® dsDNA HS Assay Kit (Thermo Fisher Scientific). 147 cfDNA was treated with bisulfite using EZ DNA Methylation-GoldTM (Zymo Research), and 148 PCR amplified with primers specific for bisulfite-treated DNA but independent of methylation status at the monitored CpG sites, as described³⁵. Treatment with bisulfite led to degradation of 149 150 60–90% of the DNA (average, 75% degradation), consistent with previous reports³⁶. Note that 151 while DNA degradation does reduce assay sensitivity (since fewer DNA molecules are available 152 for PCR amplification), it does not significantly harm assay specificity since methylated and 153 unmethylated molecules are equally affected. Primers were bar-coded using TruSeq Index 154 Adapters (Illumina), allowing the mixing of samples from different individuals when sequencing 155 PCR products using NextSeq sequencers (Illumina). Sequenced reads were separated by barcode, 156 aligned to the target sequence, and analyzed using custom scripts written and implemented in R. 157 Reads were quality filtered based on Illumina quality scores, and identified by having at least 158 80% similarity to target sequences and containing all the expected CpGs in the sequence. CpGs 159 were considered methylated if CG was read and were considered unmethylated if TG was read.

- 160 The fraction of unmethylated molecules in a sample was multiplied by the total concentration of
- 161 cfDNA in the sample, to assess the number of brain genome equivalents per ml of plasma. The
- 162 concentration of cfDNA was measured prior to bisulfite conversion, rendering the assay robust to
- 163 potential inter-sample fluctuations in the extent of bisulfite-induced DNA degradation.

165 **Results**

166 Identification of brain methylation markers

167 Tissue-specific methylation markers were selected after a comparison of extensive genome-wide

- 168 DNA methylation datasets generated using Illumina Infinium HumanMethylation450k BeadChip
- 169 array. Datasets used included publicly available methylation profiles from The Cancer Genome
- 170 Atlas and Gene Expression Omnibus repositories, along with data that we generated locally.
- 171 Using this comparative analysis we selected 13 genomic loci, which are unmethylated
- 172 specifically in neurons (4 markers), oligodendrocytes (3 markers), or astrocytes (3 markers) and
- in all brain-derived cell types (3 markers), and methylated in all other examined cell types. Data
- 174 describing the development and validation of these 10 cell-specific markers (neurons,
- 175 oligodendrocytes and astrocytes) were published in a recent paper³⁷. To test our *in silico*
- 176 predictions regarding the 3 whole brain markers specificity, we applied bisulfite treatment,
- 177 multiplex PCR and next-generation sequencing to determine the methylation status of each
- 178 marker in a panel of DNA samples obtained from multiple human tissues, as previously
- 179 described³⁵ (**Figure 1-figure supplement 1A**). To determine assay sensitivity, we serially
- 180 diluted brain DNA into leukocyte DNA, and found that the brain markers allowed the detection
- 181 of as little as 0.1% brain DNA in a mixture, or just one brain genome in a mixture of a thousand
- 182 genomes (Figure 1-figure supplement 1B).

183 Noninvasive detection of brain-derived cfDNA among patients with first psychotic episode

- 184 We determined the plasma concentrations of brain-derived cfDNA (including methylation
- 185 markers of neurons, astrocytes, and oligodendrocytes and whole brain) in 31 healthy controls,
- and 29 patients with first psychotic episode.

187 Total levels of cfDNA circulating in plasma were higher in patients with first psychotic episode 188 compared with healthy controls (Mann–Whitney test for controls vs. patients, p-value =0.017, 189 Figure 1A). cfDNA levels from all brain cell combined were higher in patients with first 190 psychotic episode compared with healthy (Figure 1B,C). cfDNA levels from each brain cell type 191 separately or from whole-brain markers were also significantly elevated in patients (Mann-192 Whitney test for patients vs controls, neurons p-value =0.0013, astrocytes p-value =0.0016, 193 oligodendrocytes p-value =0.0129, whole brain markers p-value = 0.0012). Elevated brain-194 derived cfDNA was seen when measuring either its absolute concentration (Figure 1D), or its 195 fraction (Figure 1-figure supplement 2A-D). This is consistent with elevated release of brain-196 derived cfDNA in patients with first psychotic episode, reflecting brain pathology, rather than a 197 non-specific effect. 198 To determine how well brain-derived cfDNA markers can distinguish patients with first 199 psychotic episode from healthy controls, we generated a receiver operating characteristic (ROC) 200 curve for the combined signal from all brain cell types. The brain cfDNA score was able to 201 identify the plasma of patients with a first psychotic episode with an area under the curve (AUC) 202 of 0.77 (p value=0.0003). At 90% specificity, the sensitivity for identifying patients with first 203 psychotic episode was 65% (Figure 1E). The markers of each brain cell type were able to 204 identify the plasma of patients with first psychotic episode with an AUC of 0.65-0.73 (Figure 1-205 figure supplement 2E-H). 206 There was no significant correlation between brain markers and clinical parameters including the 207 duration of the current episode, duration of hospitalization or the number of psychotic episodes 208 (see Data Table S1).

209 Relationship to psychiatric drugs

210 Since previous studies found a correlation between the use of antipsychotic drugs and anatomic changes in the brain³⁸, we examined whether the increase of brain-derived cfDNA levels in 211 212 patients is related to their psychiatric drug intake. To this effect, we considered (1) the amount of 213 antipsychotic drugs taken on the day of the patient's blood test for cfDNA, and (2) the total 214 amount of antipsychotic drugs taken throughout the hospitalization until the blood test. These 215 data were taken from medical records. In order to generate a single score for all patients, 216 independently of the type of drugs they took, we converted the various antipsychotic medication 217 dosages into an equivalent dosage of olanzapine, following the expert-consensus based method used in Gardner et. al (2010)³⁹. We then ran various statistical tests (Pearson and Spearman 218 219 correlation coefficients, and t-test and Mann-Whitney for categorical comparisons), to examine 220 potential correlations with the total amount of cfDNA, and the level of cfDNA originating from 221 astrocytes, neurons, oligodendrocytes, and from the whole brain. We considered 13 individual 222 biomarkers for brain cell types, as well as their average for each cell type, for a total of 18 223 variables.

After correcting for multiple testing, we did not find any statistically significant correlation between drug intake and cfDNA. Also, all statistical tests apart from 3 were non-significant on a nominal level (p>0.05). We found nominally statistically significant correlations between the levels of brain-derived cfDNA and drug intake for only one type of astrocyte marker (PRDM2) and one type of neuron marker (ITF) (Spearman correlation coefficient for astrocyte marker PRDM2: p-value=0.024/drugs on blood test day, and p-value=0.025/overall amount drugs; for neuron ITF: p-value=0.016/overall amount of drugs).

232 **Discussion**

We have demonstrated increased levels of brain-derived cfDNA in adult patients with a first
psychotic episode. This is a proof-of-concept study, demonstrating the feasibility of using
cfDNA as a biomarker in psychiatric patients, and the results call for replication in a larger
number of well characterized patient samples, requiring better control for diagnosis and drug
treatment. Further research is needed to examine the association of increased brain cfDNA levels
with specific diagnoses, mainly schizophrenia, and with other factors such as genetic
predisposition and course of disease.

240 We note that our study detected elevated brain cfDNA but did not reveal the cause of release of 241 these molecules to circulation. We hypothesize that our findings reflect brain cell apoptosis, 242 which is consistent with the literature indicating brain damage in such patients. However 243 elevated brain cfDNA could also result from a disruption of the blood-brain barrier, from a 244 defect in the local removal of debris from dying brain cells, or a combination of these biological phenomena. Regardless, elevated brain cfDNA provides an intriguing, measurable link between 245 246 a physical process in the brain and a psychotic episode. Another alternative driver of cfDNA, 247 which we could not robustly rule out, was psychiatric drug treatment or illicit drug abuse both of 248 which could theoretically induce brain cell death, although we partially controlled for that. 249 Future exploration should aim at distinguishing between these possibilities. We also note that 250 samples were obtained after the initial stabilization and partial remission of the psychotic 251 symptoms, suggesting the possibility that a more dramatic elevation of brain cfDNA takes place 252 during the acute phase of the psychotic episode. Finally, we observed an elevation in the total 253 concentration of cfDNA among psychotic patients. Since brain cfDNA comprises a small 254 fraction of cfDNA even among patients (<1% of total cfDNA), this elevation must originate in

- 255 other tissues, likely immune or inflammatory cells, perhaps related to the proposed link between
- 256 schizophrenia and the immune system 40,41 .
- 257 The development and validation of brain-specific cfDNA methylation markers can shed light on
- the biology of schizophrenia and other brain diseases, and potentially assist early detection and
- 259 monitoring of treatment response.

261 Competing interests

- 262 DN, HZ, BG, RS, and YD filed a patent (year 2019, application number 62/828,587) on cell-free
- 263 DNA analysis technology. The remaining authors declare no competing interests.

264

265 Funding

- 266 Supported by a Joint Award of the National Institute of Psychobiology in Israel (NIPI) and the
- 267 Israeli Society of Biological Psychiatry (to IP and AL). Supported by grants from Grail, The
- 268 Ernest and Bonnie Beutler Research Program of Excellence in Genomic Medicine, The Israel
- 269 Science Foundation, the Waldholtz/Pakula family, the Robert M. and Marilyn Sternberg Family
- 270 Charitable Foundation (to YD). YD holds the Walter and Greta Stiel Chair and Research grant in

Heart studies.

272

273 Acknowledgements

The authors thank all patients and controls for their participation in the study.

275

276 Code availability

277 Custom script for sequence analysis is available from the authors upon reasonable request.

278

279 Data availability

- 280 All relevant data including information on the markers used (coordinates and primer sequences),
- 281 detailed information on donors and the raw data on values of each methylation marker in each

- 282 sample is provided within the supplementary information. Detailed PCR conditions and
- additional protocols are available from the authors upon reasonable request.

284 **References**

285	1.	Laursen,	T. M., Nord	lentoft, M. &	& Mortensen, P	P. B. Excess	early mortality in	l
-----	----	----------	-------------	---------------	----------------	--------------	--------------------	---

- 286 schizophrenia. Annual Review of Clinical Psychology vol. 10 425–448 (2014).
- 287 2. Chong, H. Y. *et al.* Global economic burden of schizophrenia: A systematic review.
- 288 *Neuropsychiatric Disease and Treatment* vol. 12 357–373 (2016).
- 289 3. Insel, T. R. Rethinking schizophrenia. *Nature* vol. 468 187–193 (2010).
- Kahn, R. S. & Sommer, I. E. The neurobiology and treatment of first-episode
 schizophrenia. *Molecular Psychiatry* vol. 20 84–97 (2015).
- 292 5. Lewandowski, K. E., Cohen, B. M. & Öngur, D. Evolution of neuropsychological
- dysfunction during the course of schizophrenia and bipolar disorder. *Psychol. Med.* 41,
 225–241 (2011).
- 295 6. Owen, M. J., Sawa, A. & Mortensen, P. B. Schizophrenia. *Lancet* **388**, 86–97 (2016).
- 296 7. Stefansson, H. *et al.* Common variants conferring risk of schizophrenia. *Nature* 460, 744–
 297 747 (2009).
- 298 8. Davison, J., O'Gorman, A., Brennan, L. & Cotter, D. R. A systematic review of
- 299 metabolite biomarkers of schizophrenia. *Schizophrenia Research* vol. 195 32–50 (2018).
- Morita, K. *et al.* Eye movement as a biomarker of schizophrenia: Using an integrated eye
 movement score. *Psychiatry Clin. Neurosci.* **71**, 104–114 (2017).
- 302 10. Suh, B. K. et al. Schizophrenia-associated dysbindin modulates axonal mitochondrial
- 303 movement in cooperation with p150glued. *Mol. Brain* **14**, (2021).

- 304 11. McCutcheon, R. A., Reis Marques, T. & Howes, O. D. Schizophrenia An Overview.
- 305 *JAMA Psychiatry* vol. 77 201–210 (2020).
- 12. Liu, Y. In Search of Darwin's Imaginary Gemmules. Adv. Genet. 101, 87–114 (2018).
- 307 13. Lo, Y. M. D., Han, D. S. C., Jiang, P. & Chiu, R. W. K. Epigenetics, fragmentomics, and
 308 topology of cell-free DNA in liquid biopsies. *Science* 372, (2021).
- 309 14. Lo, Y. M. D. *et al.* Rapid Clearance of Fetal DNA from Maternal Plasma. *Am. J. Hum.*310 *Genet.* (1999) doi:10.1086/302205.
- 311 15. Sherwood, K. & Weimer, E. T. Characteristics, properties, and potential applications of
 312 circulating cell-free dna in clinical diagnostics: a focus on transplantation. *Journal of*
- 312 circulating cell-free dna in clinical diagnostics: a focus on transplantation. *Journal of*313 *Immunological Methods* vol. 463 27–38 (2018).
- 314 16. Wainscoat, J. S. *et al.* Presence of fetal DNA in maternal plasma and serum. *Lancet* 350,
 315 485–487 (2002).
- 316 17. Wong, B. C. K. & Lo, Y. M. D. Cell-free DNA and RNA in plasma as new tools for
- 317 molecular diagnostics. *Expert Review of Molecular Diagnostics* vol. 3 785–797 (2003).
- 318 18. Volckmar, A. L. *et al.* A field guide for cancer diagnostics using cell-free DNA: From
 319 principles to practice and clinical applications. *Genes Chromosomes and Cancer* vol. 57
- 320 123–139 (2018).
- 321 19. Schwarzenbach, H., Hoon, D. S. B. & Pantel, K. Cell-free nucleic acids as biomarkers in
 322 cancer patients. *Nature Reviews Cancer* (2011) doi:10.1038/nrc3066.
- 323 20. Corcoran, R. B. & Chabner, B. A. Application of Cell-free DNA Analysis to Cancer

324 Treatment. N. Engl. J. Med. **379**, 1754–1765 (2018).

325	21.	Lehmann-Werman.	R.	et al.	Monitoring	liver	damage	using h	epatocyte-	specific
222		Dennianni () ernnang		<i>ci cii</i> .	1010111COTING		aannage	woning i		specifie

- 326 methylation markers in cell-free circulating DNA. *JCI Insight* (2018)
- doi:10.1172/jci.insight.120687.
- 328 22. Gala-Lopez, B. L. *et al.* Beta Cell Death by Cell-free DNA and Outcome After Clinical
 329 Islet Transplantation. *Transplantation* 102, 978–985 (2018).
- 330 23. Lehmann-Werman, R. et al. Identification of tissue-specific cell death using methylation
- 331 patterns of circulating DNA. *Proc. Natl. Acad. Sci.* (2016) doi:10.1073/pnas.1519286113.
- Zemmour, H. *et al.* Non-invasive detection of human cardiomyocyte death using
 methylation patterns of circulating DNA. *Nat. Commun.* (2018) doi:10.1038/s41467-01803961-y.
- Sun, K. *et al.* Plasma DNA tissue mapping by genome-wide methylation sequencing for
 noninvasive prenatal, cancer, and transplantation assessments. *Proc. Natl. Acad. Sci.*
- 337 (2015) doi:10.1073/pnas.1508736112.
- 338 26. Gai, W. et al. Liver- and Colon-Specific DNA Methylation Markers in Plasma for

339 Investigation of Colorectal Cancers with or without Liver Metastases. *Clin. Chem.* 64,

340 1239–1249 (2018).

- 341 27. Moss, J. *et al.* Comprehensive human cell-type methylation atlas reveals origins of
 342 circulating cell-free DNA in health and disease. *Nat. Commun.* 9, (2018).
- 343 28. Dor, Y. & Cedar, H. Principles of DNA methylation and their implications for biology and
 344 medicine. *The Lancet* (2018) doi:10.1016/S0140-6736(18)31268-6.

345	29.	Takahashi, T. & Suzuki, M. Brain morphologic changes in early stages of psychosis:
346		Implications for clinical application and early intervention. <i>Psychiatry Clin. Neurosci.</i> 72,
347		556–571 (2018).
348	30.	Dietsche, B., Kircher, T. & Falkenberg, I. Structural brain changes in schizophrenia at
349		different stages of the illness: A selective review of longitudinal magnetic resonance
350		imaging studies. Australian and New Zealand Journal of Psychiatry vol. 51 500-508
351		(2017).
352	31.	Pantelis, C. et al. Neuroimaging and emerging psychotic disorders: The Melbourne ultra-
353		high risk studies. International Review of Psychiatry vol. 19 371–379 (2007).
354	32.	Jarskog, L. F., Glantz, L. A., Gilmore, J. H. & Lieberman, J. A. Apoptotic mechanisms in
355		the pathophysiology of schizophrenia. Progress in Neuro-Psychopharmacology and
356		Biological Psychiatry vol. 29 846–858 (2005).
357	33.	Jarskog, L. F. Apoptosis in schizophrenia: Pathophysiologic and therapeutic
358		considerations. Current Opinion in Psychiatry vol. 19 307-312 (2006).
359	34.	Ershova, E. S. et al. Quantification of cell-free DNA in blood plasma and DNA damage
360		degree in lymphocytes to evaluate dysregulation of apoptosis in schizophrenia patients. J.
361		<i>Psychiatr. Res.</i> 87, 15–22 (2017).
362	35.	Neiman, D. et al. Multiplexing DNA methylation markers to detect circulating cell-free
363		DNA derived from human pancreatic beta-cells. JCI Insight (2020)
364		doi:10.1172/jci.insight.136579.
365	36.	Grunau, C., Clark, S. J. & Rosenthal, A. Bisulfite genomic sequencing: systematic

366		investigation of critical experimental parameters. Nucleic Acids Res. 29, 65-65 (2001).
367	37.	Lubotzky, A. et al. Liquid biopsy reveals collateral tissue damage in cancer. JCI insight 7,
368		(2022).
369	38.	Huhtaniska, S. et al. Long-term antipsychotic use and brain changes in schizophrenia – a
370		systematic review and meta-analysis. Human Psychopharmacology vol. 32 (2017).
371	39.	Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F. & Baldessarini, R. J.
372		International consensus study of antipsychotic dosing. Am. J. Psychiatry 167, 686-693
373		(2010).
374	40.	KE, Z. & JR, L. Innate immunity at the crossroads of healthy brain maturation and
375		neurodevelopmental disorders. Nat. Rev. Immunol. 21, (2021).
376	41.	GM, K. et al. Inflammation and immunity in schizophrenia: implications for
377		pathophysiology and treatment. The lancet. Psychiatry 2, 258–270 (2015).
378		

379 Legend to Figure

380

Figure 1: Brain-derived cfDNA in patients with a first psychotic episode.

382 A. Plasma concentrations of total cfDNA. Total levels of cfDNA in healthy controls and

383 patients with first psychotic episode. Mann–Whitney test for controls vs. patients, p-value

384 =0.017.

385 **B-C. Plasma concentrations of brain-derived cfDNA.** Brain cfDNA levels in healthy controls

386 (n=31) and patients with first psychotic episode (n=29), represented as the cumulative sum of the

387 average signals from neuron, oligodendrocyte and astrocyte markers. In panel B, graph retaining

388 the value of each component; in panel C, graph combining all average signals to one value for

389 statistical analysis.

D. Signals from distinct brain cell types. Mann–Whitney test for controls vs. patients, neurons

391 p-value =0.0013, astrocytes p-value =0.0016, oligodendrocytes p-value =0.0129 and whole brain

392 markers p-value =0.0012. Shown are the average levels in plasma of 4 neuronal markers, 3

393 astrocyte markers, 3 oligodendrocyte markers, and 3 general brain markers. cfDNA was treated

394 with bisulfite, PCR amplified and sequenced, and the molecules that are fully unmethylated were

395 scored. The fraction of brain-specific molecules was multiplied by the total cfDNA

396 concentration. Each dot represents one plasma sample.

E. ROC curve for distinguishing patients with first psychotic episode from healthy controls.

A combined score of all brain markers, area under the curve (AUC) 0.77; 95% CI =0.64-0.9; p-

399 value = 0.0003.

401 Legend to Supplementary Figures

402

403 Figure 1-figure supplement 1: specificity and sensitivity of brain methylation markers.

- 404 A. Methylation status of 13 brain-derived markers in genomic DNA from multiple human
- 405 tissues. Each color represents a different locus that is differentially hypomethylated in a specific
- 406 brain cell type. Shown is the methylation score of multiple CpG sites in each block (i.e. the
- 407 fraction of molecules that are fully unmethylated in a given sample).
- 408 **B**. Sensitivity of brain-derived methylation markers. Brain DNA was spiked into leukocyte DNA
- 409 as indicated and the fraction of brain DNA was assessed using bisulfite conversion, multiplex
- 410 PCR amplification of brain markers and sequencing. Left. 20 brain cell genome equivalents
- 411 (GE) (120 pg brain DNA) were mixed with blood DNA (0 to 10 ng). **Right**, brain cell DNA (20
- 412 to 0.2 GE) was diluted into 10ng of blood DNA.
- 413
- Figure 1-figure supplement 2: fractions and ROC curves for markers of individual brain
 cell types.
- 416 **A-D: Percentage of brain-derived cfDNA.**
- 417 Brain cfDNA levels expressed as percentage of cfDNA derived from the indicated brain cell
- 418 type. Mann–Whitney test for controls vs. patients, neurons p-value =0.0048, astrocytes p-value
- 419 =0.0074, oligodendrocytes p-value =0.0186 and whole brain markers p-value =0.0018.

420 E-H: ROC curves for distinguishing patients with first psychotic episode from healthy

421 controls, using markers of individual brain cell types.

- **E.** Neuronal markers; area under the curve (AUC) 0.73, 95% CI = 0.6 to 0.86; p-value < 0.0024.
- **F**. Astrocyte markers; AUC 0.73; 95% CI = 0.6 to 0.86; p-value < 0.0024.
- **G**. Oligodendrocyte markers; AUC 0.65; 95% CI = 0.51 to 0.79; p-value < 0.045.
- **H**. Whole brain markers; AUC 0.71; 95% CI = 0.58 to 0.84; p-value < 0.0036.

Figure 1





Figure 1-figure supplement 1



Figure 1-figure supplement 2

